NIL
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Dedication - p. v 6. Preface - p. vii 7. List of Contributors - p. ix 8. List of Illustrations - p. xiii 9. List of Tables - p. xiv 10. 1. Lung cancer screening and prevention - p. 1 11. 2. Lung cancer: Diagnostic techniques - p. 35 12. 3. Histology and molecular testing - p. 69 13. 4. Surgical considerations in lung cancer treatment - p. 101 14. 5. Surgically resectable disease - p. 119 15. 6. Oligometastatic disease - p. 137 16. 7. Locally advanced non–small cell lung cancer - p. 155 17. 8. First-line therapy - p. 175 18. 9. Second-line therapy in advanced non–small cell lung cancer - p. 195 19. 10. Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach - p. 217 20. 11. Diagnosis a nd treatment of anaplastic lymphoma kinase (ALK) rearranged non−small cell lung cancer - p. 253 21. 12. Other molecular cohorts including ROS1, BRAF, HER2, MET, NT RK, RET, KRAS - p. 269 22. 13. Immunotherapy - p. 283 23. 14. Small cell lung cancer - p. 305 24. Index - p. 325
NIL
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Dedication - p. v 6. Preface - p. vii 7. List of Contributors - p. ix 8. List of Illustrations - p. xiii 9. List of Tables - p. xiv 10. 1. Lung cancer screening and prevention - p. 1 11. 2. Lung cancer: Diagnostic techniques - p. 35 12. 3. Histology and molecular testing - p. 69 13. 4. Surgical considerations in lung cancer treatment - p. 101 14. 5. Surgically resectable disease - p. 119 15. 6. Oligometastatic disease - p. 137 16. 7. Locally advanced non–small cell lung cancer - p. 155 17. 8. First-line therapy - p. 175 18. 9. Second-line therapy in advanced non–small cell lung cancer - p. 195 19. 10. Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach - p. 217 20. 11. Diagnosis a nd treatment of anaplastic lymphoma kinase (ALK) rearranged non−small cell lung cancer - p. 253 21. 12. Other molecular cohorts including ROS1, BRAF, HER2, MET, NT RK, RET, KRAS - p. 269 22. 13. Immunotherapy - p. 283 23. 14. Small cell lung cancer - p. 305 24. Index - p. 325
